BNP Paribas Financial Markets
TERN

BNP Paribas Financial Markets’s Terns Pharmaceuticals TERN Stock Holding History

BNP Paribas Financial Markets’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.57M Buy
67,695
+47,342
+233% +$1.94M ﹤0.01% 2275
2025
Q4 		$822K Sell
20,353
-65,956
-76% -$1.52M ﹤0.01% 3249
2025
Q3 		$648K Sell
86,309
-420,468
-83% -$2.68M ﹤0.01% 3418
2025
Q2 		$1.89M Buy
506,777
+52,796
+12% +$165K ﹤0.01% 2506
2025
Q1 		$1.25M Buy
453,981
+229,716
+102% +$938K ﹤0.01% 2617
2024
Q4 		$1.24M Buy
+224,265
New +$1.52M ﹤0.01% 2676

Other funds holding TERN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

BNP Paribas Financial Markets's TERN Position: Q1 2026 in Review

BNP Paribas Financial Markets increased its Terns Pharmaceuticals (TERN) stake by 233% in Q1 2026, buying an estimated $1.94M and bringing the position to 67,695 shares worth $3.57M. The position accounts for ﹤0.01% of the portfolio, ranked #2275.

BNP Paribas Financial Markets first reported a position in TERN in Q4 2024 and has held it in 6 quarters since. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • BNP Paribas Financial Markets held 67,695 shares of Terns Pharmaceuticals worth $3.57M as of Q1 2026.
  • BNP Paribas Financial Markets bought 47,342 Terns Pharmaceuticals shares in Q1 2026, an estimated $1.94M.
  • Terns Pharmaceuticals made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #2275 holding.
  • BNP Paribas Financial Markets first reported a position in Terns Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.